Teva Pharmaceuticals has announced its Sudocrem factory in Baldoyle in Dublin is reportedly due to close next year, with the loss of over 100 jobs.
Sudocrem Antiseptic Healing Cream is manufactured in Ireland by Forest Tosara Ltd.
The company made the announcement today having met with staff at the northside facility yesterday, reports Independent.ie.
“Yesterday we met with employees at our Baldoyle plant to inform them of the proposed closure of the site, as part of a wider programme to optimise our global manufacturing network," a Teva spokesman said.
“We know that this news is disappointing for many, but we’ll do everything we can to support all our affected employees throughout this process,” he added.
The versatile product is which is used for treating nappy rash, eczema, pressure sores, incontinence rash and a variety of other minor skin lesions has been produced in Baldoyle since the 1940s.
It is believed that a number of its employees have been working in the Baldoyle plant for over 20 years.
Speaking with the Irish Independent one worker said, “We are devastated, no talks have started yet so we are taking the weekend to let it sink in and see what's on offer.”
The Teva spokesman said that the company will continue to have a strong presence in Ireland through its respiratory manufacturing plant in Waterford in addition to its commercial activities and will remain committed to the Irish market.
The manufacturing of Sudocrem is planned to be moved to Bulgaria in 2022.
Sudocrem was developed in 1931 by a Dublin-based pharmacist Thomas Smith.
The iconic brand was launched nationally in Great Britain and over the next 20 years quickly established itself as the market leader for nappy rash cream in the UK and Ireland.
Sudocrem products are now available in over 40 countries worldwide.